COPANLISIB IN COMBINATION WITH ANTI‐PD‐1 INDUCES REGRESSION IN ANIMAL TUMOR MODELS INSENSITIVE OR RESISTANT TO THE MONOTHERAPIES OF PI3K AND CHECKPOINT INHIBITORS. (June 2017) - Liu, N.; Haike, K.; Glaeske, S.; Paul, J.; Mumberg, D.; Kreft, B.; Ziegelbauer, K.